| Code | CSB-RA614990MB2HU |
| Size | |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the therapeutic monoclonal antibody Girentuximab, targeting carbonic anhydrase IX (CA9), a transmembrane metalloenzyme that catalyzes the reversible hydration of carbon dioxide to bicarbonate and protons. CA9 plays a critical role in pH regulation and is characteristically overexpressed in hypoxic tumor microenvironments, particularly in renal cell carcinoma, where it serves as a diagnostic and prognostic biomarker. The enzyme's expression is tightly regulated by hypoxia-inducible factor 1-alpha (HIF-1α) and is associated with tumor cell survival, proliferation, and metastasis under oxygen-deprived conditions. Elevated CA9 expression has been documented in various solid tumors including clear cell renal carcinoma, cervical cancer, and certain lung cancers.
This CA9 (Girentuximab Biosimilar) Recombinant Monoclonal Antibody exhibits Human species reactivity. Its immunogen is Recombinant Human CA9 protein. As a biosimilar to the reference Girentuximab antibody, this reagent provides researchers with a reliable tool for investigating CA9 expression patterns, studying hypoxia-related tumor biology, and exploring potential therapeutic interventions targeting the tumor microenvironment. It supports oncology research focused on understanding cancer metabolism and developing novel diagnostic or therapeutic strategies.
There are currently no reviews for this product.